Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit.

Study Overview

• Status: Completed
• Conditions: Obstructive Sleep Apnea; Hypopnea
• Intervention / Treatment: Drug: Armodafinil 250 mg/day; Drug: Armodafinil 150 mg/day; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 395
• Phase: Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients are included in the study if all of the following criteria are met:

1. Written informed consent is obtained.
2. The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive).
3. The patient has a complaint of excessive sleepiness despite nCPAP therapy being effective and being a regular user of nCPAP therapy.
4. The patient has a current diagnosis of OSAHS according to International Classification of Sleep Disorders (ICSD) criteria.

5. The patient meets the following nCPAP therapy requirements:

   • Adequate education and intervention efforts to encourage nCPAP therapy use must be documented.
   • A patient's nCPAP therapy regimen must be stable for at least 4 weeks.
   • nCPAP therapy is shown to be effective, with effectiveness defined as having an apnea-hypopnea index (AHI) of 10 or less during nocturnal PSG, and, in the opinion of the investigator, nCPAP is effective therapy.
   • Following demonstration of effectiveness, evidence of regular nCPAP usage must be shown during a 2-week evaluation period (ie, nCPAP usage for at least 4 hours/night on at least 70% of the nights).
6. The patient is in good health as determined by a medical and psychiatric history, physical examination, ECG, and serum chemistry and hematology.
7. Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of the study.
8. The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more.
9. The patient has an ESS score of 10 or more.
10. The patient does not have any medical or psychiatric disorders that could account for the excessive sleepiness.
11. The patient is able to complete self rating scales and computer-based testing.
12. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

Exclusion Criteria:

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

1. has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)
2. has a probable diagnosis of a current sleep disorder other than OSAHS
3. consumes caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day
4. used any prescription drugs disallowed by the protocol or clinically significant use of over the-counter (OTC) drugs within 7 days before the second screening visit
5. has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)
6. has a positive urine drug screen (UDS)
7. has a clinically significant deviation from normal in the physical examination
8. is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)
9. has used an investigational drug within 1 month before the initial screening visit
10. has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)
11. has a known clinically significant drug sensitivity to stimulants or modafinil

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 3; Placebo	Drug: Placebo; Matching placebo tablets once daily in the morning
Experimental: 2; Armodafinil 150 mg/day	Drug: Armodafinil 150 mg/day; Armodafinil 150 mg once daily in the morning; Other Names: CEP-10953; NUVIGIL
Experimental: 1; Armodafinil 250 mg/day	Drug: Armodafinil 250 mg/day; Armodafinil 250 mg once daily in the morning; Other Names: CEP-10953; NUVIGIL

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maintenance of Wakefulness Test (MWT)	The MWT is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient's ability to remain awake. The primary variable was the 30 minute MWT (average of 4 naps at 0900, 1100, 1300, and 1500) assessed at the last postbaseline observation.	change from baseline at 12 weeks
Clinical Global Impression of Change (CGI-C)	The CGI-C represents a subjective measure of the patient's global health (clinician's rating of disease severity as compared with a pretreatment evaluation as assessed by the CGI-S). The CGI-C scale (change from baseline)categories include:1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness (CGI-S) was assessed at baseline includes categories: 1=Normal; 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.	change from baseline at 12 weeks

Collaborators and Investigators

• Sponsor: Cephalon

Study record dates

Study Major Dates

• Study Start: February 1, 2004
• Primary Completion (Actual): November 1, 2004
• Study Completion (Actual): November 1, 2004

Study Registration Dates

• First Submitted: February 23, 2004
• First Submitted That Met QC Criteria: February 24, 2004
• First Posted (Estimate): February 25, 2004

Study Record Updates

• Last Update Posted (Estimate): July 19, 2013
• Last Update Submitted That Met QC Criteria: July 12, 2013
• Last Verified: July 1, 2013

More Information

Terms related to this study

• Keywords: Obstructive Sleep Apnea; nCPAP; Excessive Sleepiness; Cephalon; Cephalon, Inc; Obstructive Sleep Hypopnea; NUVIGIL
• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Signs and Symptoms, Respiratory; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Apnea; Sleepiness; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Central Nervous System Stimulants; Wakefulness-Promoting Agents; Modafinil
• Other Study ID Numbers: C10953/3021/AP/MN